Teva Pharmaceutical Industries Limited filings document material events, operating and financial results, capital-structure matters, governance, and shareholder voting for the Israel-based pharmaceutical issuer. Its 8-K reports include results announcements, conference-related outlook disclosures, and material definitive agreements, including amendments to a senior unsecured sustainability-linked revolving credit facility.
Teva's proxy materials cover annual meeting procedures, shareholder proposals, governance matters, and annual consolidated financial statements. The filing record also identifies the company's American Depositary Shares, each representing one ordinary share, as securities registered for trading under TEVA on the New York Stock Exchange.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at a stated price of $0.00 per share.
After this non-cash equity compensation event, Elstein directly held 2,118,455 ordinary shares. Each restricted share unit provided a contingent right to receive one ordinary share or, at the company committee’s option, the cash value of one ordinary share. No open-market buy or sell transaction was reported in this filing.
Teva Pharmaceutical Industries director Gerald M. Lieberman exercised restricted share units into ordinary shares. On June 5, 2026, he acquired 14,492 ordinary shares at a stated price of $0.00 per share through the vesting and conversion of restricted share units granted on June 5, 2025.
Following this transaction, he directly holds 130,149 ordinary shares. The footnotes note that each restricted share unit entitled him, at settlement, to receive one ordinary share or the cash value of one ordinary share, and that ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were settled into 14,492 ordinary shares, bringing Perry’s direct holdings to 119,807 ordinary shares.
Teva Pharmaceutical Industries director Ronit Satchi-Fainaro exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units converted into 14,492 ordinary shares at a stated exercise price of $0.00 per unit, reflecting RSU vesting rather than an open-market purchase.
These RSUs were originally granted on June 5, 2025 and vested on June 5, 2026. After the settlement, Satchi-Fainaro directly holds 112,401 ordinary shares. The filing shows an acquisition of shares through equity compensation, with no reported open-market buying or selling.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.
Teva Pharmaceutical Industries director Roberto Mignone reported exercising restricted share units into 14,492 Ordinary Shares on June 5, 2026, at a stated price of $0.00 per share. Following this, he directly holds 119,807 Ordinary Shares.
A separate 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd., advised by Bridger Management, LLC, which Mignone manages. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.
Teva Pharmaceutical Industries President and CEO Richard D. Francis reported routine equity compensation activity involving restricted share units and related share sales. He exercised 13,043 restricted share units into ordinary shares and sold 6,153 ordinary shares at $34.35 per share to cover tax withholding obligations tied to the vesting. Following these transactions, he directly holds 1,177,529 ordinary shares and 39,130 restricted share units, with the sale executed under a pre-arranged Rule 10b5-1 trading plan.
TEVA notice reports a proposed resale of 13,043 ordinary shares tied to a restricted share unit award vesting on 06/05/2026. The filing also records a prior sale of 20,025 ordinary shares on 03/05/2026 for $634,159.71.
Teva Pharmaceutical Industries executive Matthew Shields exercised 16,195 restricted share units into ordinary shares and on the same day sold all 16,195 shares at an average price of $32.87. The sale, which also covered tax withholding obligations from vesting, was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these transactions, Shields directly holds 9,989 ordinary shares.
Teva Pharmaceutical Industries Limited filed a Rule 144 notice reporting proposed sales of 16,195 Ordinary Shares. The filing lists the securities as resulting from a Restricted Share Unit award vesting with an execution date shown as 06/03/2026. The excerpt also records a prior sale of 17,295 shares on 03/05/2026 for $547,704.98.